Assessment and Tracking of Long-term Alefacept Safety (ATLAS)

Astellas

Status: Terminated

Conditions: Psoriasis

Treatments: Drug: Alefacept exposure

Study type: Observational

Funder types: Industry

Identifiers

NCT00454701

0485-CL-0001

C-736

Details and patient eligibility

About

Subjects exposed to alefacept are to be enrolled. Subjects will be contacted every 6 months to gather general health information.

Full description

There are no study-mandated tests, visits or clinical interventions after the 1st (enrolling) visit. After the patient is enrolled in the study, they will be contacted every 6 months to complete structured telephone interviews conducted by the ATLAS Study Center.

Enrollment: 1,897 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Psoriasis patients who are prescribed alefacept consistent with product labeling are eligible for enrollment.

Trial design

1,897 participants in 1 patient group

1. Amevive Exposure

Description:

Patients treated with alefacept for chronic plaque psoriasis

Treatment:

Drug: Alefacept exposure